Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 4Stomatitis 3Neoplasm Metastasis 2Head and Neck Neoplasms 2Cancer Pain 2Thromboembolism 1Successful Conversion Rate of Operation 1Sarcoma 1Respiratory Insufficiency 1Prostatic Neoplasms 1Pneumonia 1Pancreatic Neoplasms 1Pain 1Myocardial Infarction 1Multiple Myeloma 1Mucositis 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Kidney Diseases 1Hematologic Neoplasms 1Arrhythmias, Cardiac 1Angina, Unstable 1Adenocarcinoma 1Acute Coronary Syndrome 1

Interventions

Oxaliplatin 46Gemcitabine 45Fluorouracil 40Capecitabine 31pembrolizumab 29Leucovorin 29Docetaxel 27Cisplatin 25Paclitaxel 23Irinotecan 18Carboplatin 18Bevacizumab 18130-nm albumin-bound paclitaxel 17Pemetrexed 15Albumin-Bound Paclitaxel 15Radiotherapy 14Nivolumab 12Ramucirumab 11Cyclophosphamide 11Trastuzumab 8Erlotinib Hydrochloride 8Taxes 7Radiosurgery 7Drug Therapy 7cemiplimab 6zolbetuximab 5trastuzumab deruxtecan 5regorafenib 5durvalumab 5Sorafenib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Adenocarcinoma × Sodium Bicarbonate × Clear all
NCT01198821 2017-02-23

Gem-TABS in Unresectable Pancreatic Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
8 enrolled
Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡